MedTrace Logo

IMGN901 in Combination With Lenalidomide and Dexamethasone

NCT00991562 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-11-21

No results posted yet for this study

Summary

The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.

Conditions

Interventions

DRUG

IMGN901

dose escalation study. dosing on days 1, 8 and 15 every 28 days

Sponsors & Collaborators

  • ImmunoGen, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-08-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00991562 on ClinicalTrials.gov